{"generic":"Ribavirin","drugs":["Copegus","Rebetol","RibaPak","Ribasphere","Ribasphere Ribapak","RibaTab","Ribavirin","Virazole"],"mono":[{"id":"b1sas0","title":"Generic Names","mono":"Ribavirin"},{"id":"b1sas1","title":"Dosing and Indications","sub":[{"id":"b1sas1b4","title":"Adult Dosing","mono":"<ul><li>assess patient's cardiovascular status (including ECG in patients with preexisting cardiac abnormalities), hematologic and biochemical laboratory values, and establish a negative pregnancy test prior to administration of ribavirin<\/li><li>oral solution may be used for any patient regardless of body weight<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease - HIV infection:<\/b> 800 mg daily ORALLY (in 2 divided doses) plus peginterferon alfa-2a 180 mcg SUBQ once weekly for 48 weeks, regardless of HCV genotype<\/li><li><b>Hepatitis C, chronic, With compensated liver disease:<\/b> (genotypes 1 and 4, with peginterferon alfa-2a) 75 kg or less, 1000 mg ORALLY daily; greater than 75 kg, 1200 mg ORALLY daily; treat for 48 weeks (guideline dosing); give in 2 divided daily doses<\/li><li><b>Hepatitis C, chronic, With compensated liver disease:<\/b> (genotypes 1 and 4, with peginterferon alfa-2b) less than 65 kg, 800 mg ORALLY daily; greater than 65 to 85 kg, 1000 mg ORALLY daily; greater than 85 kg to 105 kg, 1200 mg ORALLY daily; greater than 105 kg, 1400 mg ORALLY daily; treat for 48 weeks (guideline dosing); give in 2 divided daily doses; may re-treat for 48 weeks if failed initial therapy (Rebetol(R))<\/li><li><b>Hepatitis C, chronic, With compensated liver disease:<\/b> (genotypes 2 and 3, with peginterferon alfa), 800 mg ORALLY daily; treat for 24 weeks (guideline dosing); give in 2 divided daily doses; may re-treat for 48 weeks if failed initial therapy (Rebetol(R))<\/li><li><b>Hepatitis C, chronic, With compensated liver disease:<\/b> (in combination with interferon alfa-2b): 75 kg or less, 400 mg ORALLY every morning and 600 mg ORALLY every evening; greater than 75 kg, 600 mg ORALLY twice daily; treat for 24 to 48 weeks in interferon-alpha naive patients or for 24 weeks if relapse following nonpegylated interferon monotherapy (Rebetol(R))<\/li><\/ul>"},{"id":"b1sas1b5","title":"Pediatric Dosing","mono":"<ul><li>assess patient's cardiovascular status (including ECG in patients with preexisting cardiac abnormalities), hematologic and biochemical laboratory values, and establish a negative pregnancy test prior to administration of ribavirin and monitor during therapy<\/li><li>oral solution may be used for any patient regardless of body weight<\/li><li>safety and efficacy of Copegus(R) have not been established in children younger than 5 years; safety and efficacy of Rebetol(R) have not been established in pediatric patients younger than 3 years<\/li><li><b>Hepatitis C, chronic, With compensated liver disease:<\/b> (2 years or older), 15 mg\/kg ORALLY daily for 48 weeks with pegylated interferon alfa-2b (guideline dosing); OR (5 years or older), 23 to 33 kg: 200 mg ORALLY twice daily; 34 to 46 kg, 200 mg ORALLY in the morning and 400 mg ORALLY in the evening; 47 to 59 kg, 400 mg ORALLY twice daily; 60 to 74 kg, 400 mg ORALLY in the morning and 600 mg ORALLY in the evening; 75 kg or greater, 600 mg ORALLY twice daily; plus peginterferon alfa-2a; treat for 24 weeks in genotypes 2 and 3, and for 48 weeks in other genotypes (Copegus(R)); OR (3 years or older), less than 47 kg, 15 mg\/kg\/day ORALLY in 2 divided doses; 47 to 59 kg, 400 mg ORALLY twice daily; 60 to 73 kg, 400 mg ORALLY in the morning and 600 mg ORALLY in the evening; greater than 73 kg, 600 mg ORALLY twice daily; plus either peginterferon alfa-2b or interferon alfa-2b; treat for 48 weeks in genotype 1, or 24 weeks in genotypes 2 and 3 (Rebetol(R))<\/li><li><b>Respiratory syncytial virus infection:<\/b> (severe cases) 20 mg\/mL solution aerosolized over 12 to 18 hours once daily for 3 to 7 days<\/li><\/ul>"},{"id":"b1sas1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, adults, Copegus(R):<\/b> CrCl 30 to 50 mL\/min, decrease ribavirin to alternating daily doses of 200 mg and 400 mg ORALLY every other day; CrCl less than 30 mL\/min or hemodialysis, decrease ribavirin to 200 mg ORALLY once daily and decrease peginterferon alfa-2a to 135 mcg SUBQ once weekly; do not attempt further decreases of ribavirin; if severe adverse reactions or laboratory abnormalities occur, discontinue ribavirin; if therapy is restarted and intolerance continues, discontinue regimen<\/li><li><b>renal impairment, Rebetol(R):<\/b> CrCl less than 50 mL\/min, use not recommended; serum creatinine greater than 2 mg\/dL, discontinue in pediatric patients<\/li><li><b>geriatrics, Rebetol(R):<\/b> initiate therapy at low end of dose range and adjust dose based on renal function findings<\/li><li><b>adverse reactions, adults, Copegus(R):<\/b> following interruption of ribavirin, may restart at 600 mg ORALLY daily with further increase to 800 mg ORALLY daily; do not resume at original assigned dose<\/li><li><b>adverse reactions, pediatrics, Copegus(R):<\/b> following interruption of ribavirin, may restart at one-half the full dose; may attempt increase to original dose if clinically warranted<\/li><li><b>anemia, adults, Copegus(R):<\/b> no cardiac disease and an Hb of less than 10 g\/dL, 200 mg ORALLY every morning and 400 mg ORALLY every evening; discontinue if Hb falls below 8.5 g\/dL; if Hb values improve, may restart at 600 mg ORALLY daily with further increase to 800 mg ORALLY daily; do not resume original assigned dose<\/li><li><b>anemia, adults, Copegus(R):<\/b> history of stable cardiac disease and a decrease in Hb of 2 g\/dL or greater during any 4-week treatment period, reduce ribavirin to 200 mg ORALLY every morning and 400 mg ORALLY every evening; discontinue if Hb less than 12 g\/dL after 4 weeks of reduced dose; if Hb values improve, may restart at 600 mg ORALLY daily with further increase to 800 mg ORALLY daily; do not resume original assigned dose<\/li><li><b>anemia, pediatrics, 23 to 33 kg, Copegus(R):<\/b> no cardiac disease and an Hb of less than 10 g\/dL OR history of stable cardiac disease and a decrease in Hb of 2 g\/dL or greater during any 4-week treatment period, 200 mg ORALLY every morning; discontinue if Hb less than 8.5 g\/dL (in patients with no cardiac disease) or less than 12 g\/dL after 4 weeks of reduced dose (in patients with history of stable cardiac disease); if Hb values improve, may restart at one-half the full dose<\/li><li><b> anemia, pediatrics, 34 to 59 kg, Copegus(R):<\/b> no cardiac disease and an Hb of less than 10 g\/dL OR history of stable cardiac disease and a decrease in Hb of 2 g\/dL or greater during any 4-week treatment period, 200 mg ORALLY every morning and 200 mg ORALLY every evening; discontinue if Hb less than 8.5 g\/dL (in patients with no cardiac disease) or less than 12 g\/dL after 4 weeks of reduced dose (in patients with history of stable cardiac disease); if Hb values improve, may restart at one-half the full dose<\/li><li><b>anemia, pediatrics, 60 kg or greater, Copegus(R):<\/b> no cardiac disease and an Hb of less than 10 g\/dL OR history of stable cardiac disease and a decrease in Hb of 2 g\/dL or greater during any 4-week treatment period, 200 mg ORALLY every morning and 400 mg ORALLY every evening; discontinue if Hb less than 8.5 g\/dL (in patients with no cardiac disease) or less than 12 g\/dL after 4 weeks of reduced dose (in patients with history of stable cardiac disease); if Hb values improve, may restart at one-half the full dose<\/li><li><b>anemia, patients without a history of cardiac disease, Rebetol(R):<\/b> Hb levels 8.5 to less than 10 g\/dL, decrease dose by 200 mg\/day (or by 400 mg\/day if patient on 1400 mg\/day dose); may reduce by another 200 mg\/day if needed; discontinue if Hb less than 8.5 g\/dL<\/li><li><b>anemia, patients with history of stable cardiac disease, Rebetol(R):<\/b> Hb level decrease of 2 g\/dL or greater during any 4-week period, decrease dose by 200 mg\/day and decrease peginterferon alfa-2b or interferon alfa-2b dose by half; discontinue therapy if Hb less than 8.5 g\/dL or less than 12 g\/dL after 4 weeks of dose reduction<\/li><li><b>leukopenia, adults, Rebetol(R):<\/b> if WBC 1 to less than 1.5 x 10(9)\/L, reduce peginterferon alfa-2b dose to 1 mcg\/kg\/week with a second dose reduction to 0.5 mcg\/kg\/week if needed (refer to peginterferon alfa-2b for further dosing guidance); reduce interferon alfa-2b dose by 50%; discontinue therapy if WBC less than 1 x 10(9)\/L<\/li><li><b>leukopenia, pediatrics, Rebetol(R):<\/b> if WBC 1 to less than 1.5 x 10(9)\/L, reduce peginterferon alfa-2b dose to 40 mcg\/m(2)\/week with a second dose reduction to 20 mcg\/m(2)\/week if needed (refer to peginterferon alfa-2b for further dosing guidance); reduce interferon alfa-2b dose by 50%; discontinue therapy if WBC less than 1 x 10(9)\/L<\/li><li><b>neutropenia, adults, Rebetol(R):<\/b> if neutrophils 0.5 to less than 0.75 x 10(9)\/L, reduce peginterferon alfa-2b dose to 1 mcg\/kg\/week with a second dose reduction to 0.5 mcg\/kg\/week if needed (refer to peginterferon alfa-2b for further dosing guidance); reduce interferon alfa-2b dose by 50%; discontinue therapy if neutrophils less than 0.5 x 10(9)\/L<\/li><li><b>neutropenia, pediatrics, Rebetol(R):<\/b> if neutrophils 0.5 to less than 0.75 x 10(9)\/L, reduce peginterferon alfa-2b dose to 40 mcg\/m(2)\/week with a second dose reduction to 20 mcg\/m(2)\/week if needed (refer to peginterferon alfa-2b for further dosing guidance); reduce interferon alfa-2b dose by 50%; discontinue therapy if neutrophils less than 0.5 x 10(9)\/L<\/li><li><b>thrombocytopenia, adults, Rebetol(R):<\/b> if platelets 25 to less than 50 x 10(9)\/L, reduce peginterferon alfa-2b dose to 1 mcg\/kg\/week with a second dose reduction to 0.5 mcg\/kg\/week if needed (refer to peginterferon alfa-2b for further dosing guidance); reduce interferon alfa-2b dose by 50%; discontinue therapy if platelets less than 25 x 10(9)\/L<\/li><li><b>thrombocytopenia, pediatrics, Rebetol(R):<\/b> if platelets 50 to less than 70 x 10(9)\/L, reduce peginterferon alfa-2b dose to 40 mcg\/m(2)\/week with a second dose reduction to 20 mcg\/m(2)\/week if needed (refer to peginterferon alfa-2b for further dosing guidance); reduce interferon alfa-2b dose by 50%; discontinue therapy if platelets less than 50 x 10(9)\/L<\/li><\/ul>"},{"id":"b1sas1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hemopoietic stem cell transplant - Respiratory syncytial virus infection<\/li><li>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease - HIV infection<\/li><li>Hepatitis C, chronic, With compensated liver disease<\/li><li>Respiratory syncytial virus infection<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Herpes simplex<\/li><li>Influenza<\/li><li>Viral hemorrhagic fever<\/li><\/ul>"}]},{"id":"b1sas2","title":"Black Box Warning","mono":"<ul><li><b>Inhalation (Powder for Solution)<\/b><br\/>Use caution when administering aerosolized ribavirin to patients requiring mechanical ventilator assistance. Sudden deterioration of respiratory function has been associated with initiation of aerosolized ribavirin in infants. Monitor respiratory function during treatment. Ribavirin is not indicated for use in adults. Ribavirin has been shown to produce testicular lesions in rodents and to be teratogenic in all animal species in which adequate studies have been conducted (rodents and rabbits).<br\/><\/li><li><b>Oral (Tablet; Capsule; Solution)<\/b><br\/>Ribavirin is not effective for monotherapy treatment of chronic hepatitis C virus infection. The primary toxicity is hemolytic anemia which may result in worsening of cardiac disease and fatal and nonfatal myocardial infarctions. Avoid use in patients with significant or unstable cardiac disease. Significant teratogenic and\/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. Ribavirin is contraindicated in women who are pregnant and in male partners of women who are pregnant. Use 2 reliable forms of contraception and avoid pregnancy during therapy and for 6 months after completion of treatment in both female patients and in female partners of male patients who are taking ribavirin.<br\/><\/li><\/ul>"},{"id":"b1sas3","title":"Contraindications\/Warnings","sub":[{"id":"b1sas3b9","title":"Contraindications","mono":"<ul><li>coadministration with didanosine; symptomatic hyperlactatemia\/lactic acidosis, peripheral neuropathy, pancreatitis, and fatal hepatic failure have been reported (oral)<\/li><li>hemoglobinopathy (eg, thalassemia major and sickle-cell anemia) (oral)<\/li><li>hypersensitivity to ribavirin or any component of the product<\/li><li>pregnant women or men whose female partners are pregnant; may cause birth defects and\/or death of the exposed fetus (oral)<\/li><li>renal impairment (CrCl less than 50 mL\/min); risk of toxicity (Rebetol(R))<\/li><\/ul>"},{"id":"b1sas3b10","title":"Precautions","mono":"<ul><li>cardiac disease, significant or unstable; potential worsening due to drug-induced hemolytic anemia; use is not recommended (oral)<\/li><li>baseline risk of severe anemia (eg, spherocytosis, history of gastrointestinal bleeding); hemolytic anemia has been reported; monitoring recommended (Copegus(R))<\/li><li>infants; risk of sudden deterioration of respiratory function with initiation; monitoring recommended (inhalation)<\/li><li>long-term use; increased risk of dry mouth and dental and periodontal disorders (Rebetol(R), in combination with interferon)<\/li><li>pancreatitis; suspend therapy if suspected, discontinue if confirmed (oral, in combination with interferon)<\/li><li>pediatric patients; may reduce growth velocity (in combination with interferon)<\/li><li>pulmonary function impairment (eg, dyspnea, pulmonary infiltrates, pneumonitis, pulmonary hypertension, pneumonia, and sarcoidosis); may be induced or exacerbated; fatal pneumonia has occurred (oral, in combination with interferon therapy)<\/li><li>renal impairment (CrCl less than 50 mL\/min); risk of toxicity; monitoring and dose adjustments are recommended (Copegus(R))<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"b1sas3b11","title":"Pregnancy Category","mono":"<ul><li>X (FDA)<\/li><li>X (AUS)<\/li><\/ul>"},{"id":"b1sas3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"b1sas4","title":"Drug Interactions","sub":[{"id":"b1sas4b13","title":"Contraindicated","mono":"<ul>Didanosine (established)<\/ul>"},{"id":"b1sas4b14","title":"Major","mono":"<ul><li>Abacavir (probable)<\/li><li>Azathioprine (probable)<\/li><li>Lamivudine (probable)<\/li><li>Mercaptopurine (probable)<\/li><li>Stavudine (probable)<\/li><li>Zalcitabine (probable)<\/li><li>Zidovudine (probable)<\/li><\/ul>"},{"id":"b1sas4b15","title":"Moderate","mono":"<ul>Interferon Alfa-2b (probable)<\/ul>"}]},{"id":"b1sas5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (pediatric, 44%), Pruritus<\/li><li><b>Endocrine metabolic:<\/b>Weight decreased (10% to 29%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (10% to 22%), Gastrointestinal symptom (pediatric, 49%), Loss of appetite (24% to 32%), Nausea (25% to 43%), Vomiting (11% to 29%)<\/li><li><b>Hematologic:<\/b>Neutropenia (8% to 40%)<\/li><li><b>Neurologic:<\/b>Asthenia (63% to 68%), Dizziness, excluding vertigo (14% to 21%), Headache (43% to 62%), Insomnia (30% to 41%)<\/li><li><b>Other:<\/b>Fatigue (pediatric, 25%), Influenza-like illness (pediatric, 91%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Hematologic:<\/b>Hemolytic anemia (10% to 13%), Thrombotic thrombocytopenic purpura (less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatotoxicity, Hyperammonemia, Hyperbilirubinemia, Increased erythrocyte destruction, Liver failure, oral, in combination with peginterferon alfa-2a (2%)<\/li><li><b>Immunologic:<\/b>Bacterial infectious disease, oral, in combination with peginterferon alfa-2a (less than 1%)<\/li><li><b>Psychiatric:<\/b>Suicide (Less than 1%)<\/li><li><b>Respiratory:<\/b>Complication of respiratory therapy procedure, Drug precipitation, Respiratory complication<\/li><\/ul>"},{"id":"b1sas6","title":"Drug Name Info","sub":{"0":{"id":"b1sas6b17","title":"US Trade Names","mono":"<ul><li>Rebetol<\/li><li>Ribasphere<\/li><li>Virazole<\/li><li>Copegus<\/li><li>RibaPak<\/li><li>RibaTab<\/li><li>Ribasphere Ribapak<\/li><\/ul>"},"2":{"id":"b1sas6b19","title":"Class","mono":"<ul><li>Antiviral<\/li><li>Guanosine Nucleoside Analog<\/li><li>Viral RNA Polymerase Inhibitor<\/li><\/ul>"},"3":{"id":"b1sas6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"b1sas6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"b1sas7","title":"Mechanism Of Action","mono":"Ribavirin has direct antiviral activity against many RNA viruses, although the mechanism of action has not been fully elucidated. Ribavirin increases the mutation frequency in the genomes of several RNA viruses and ribavirin triphosphate inhibits hepatitis C viral polymerase activity.<br\/>"},{"id":"b1sas8","title":"Pharmacokinetics","sub":[{"id":"b1sas8b23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 2 hours  to 3 hours.<\/li><li>Tmax, Oral, liver impairment: 1.3 to 1.6 hours<\/li><li>Bioavailability, Oral, solution or capsule: 64%<\/li><li>Effect of food: 70% increase in AUC and Cmax with high-fat meal<\/li><\/ul>"},{"id":"b1sas8b24","title":"Distribution","mono":"<ul><li>Vd: 2859 L<\/li><li>Protein binding: not protein bound<\/li><\/ul>"},{"id":"b1sas8b25","title":"Metabolism","mono":"<ul><li>Ribavirin monophosphate: active<\/li><li>Ribavirin diphosphate: active<\/li><li>Ribavirin triphosphate: active<\/li><\/ul>"},{"id":"b1sas8b26","title":"Excretion","mono":"<ul><li>Renal: 61%<\/li><li>Fecal: 12%<\/li><li>Renal clearance: renal impairment, reduced by 30%<\/li><li>Dialyzable: Yes (hemodialysis), 50%<\/li><li>Total body clearance, adults: 26 L\/hr  to 38.2 L\/hr<\/li><li>Total body clearance, pediatrics: 0.27 L\/hr\/kg<\/li><\/ul>"},{"id":"b1sas8b27","title":"Elimination Half Life","mono":"<ul><li>Oral, 298 hours<\/li><li>Inhalation, 9.5 hours<\/li><\/ul>"}]},{"id":"b1sas9","title":"Administration","mono":"<ul><li><b>Inhalation<\/b><br\/><ul><li>pregnant healthcare workers should not administer; if this is unavoidable, follow proper procedures for minimizing exposure<\/li><li>reconstitute powder with minimum of 75 mL sterile water for injection or inhalation (preservative-free) in the original vial and shake well; transfer to a 500 mL SPAG-2 reservoir and further dilute to a final volume of 300 mL with sterile water for injection or inhalation (preservative-free) to a concentration of 20 mg\/mL<\/li><li>only administer with SPAG-2 small particle aerosol generator<\/li><li>do not administer as a mixture with other aerosolized medications<\/li><li>inspect solution for particulate matter and discoloration prior to administration<\/li><li>discard solution in the SPAG-2 unit at least every 24 hours<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>pediatric patients who reach their eighteenth birthday while receiving peginterferon alfa-2b (Pegintron(TM)) and ribavirin should remain on the pediatric dosing regimen<\/li><li>take with food<\/li><li>(Rebetol(R)), capsules should not be opened, crushed, or broken<\/li><\/ul><\/li><\/ul>"},{"id":"b1sas10","title":"Monitoring","mono":"<ul><li>virologic response (hepatitis C RNA levels) after 12 and 24 weeks of therapy<\/li><li>improvement in hepatic function test results and in signs and symptoms of hepatitis C<\/li><li>improvement in signs and symptoms of respiratory infection<\/li><li>CBC with differential (Hgb or HCT at wk 2 and 4, or more frequently if clinically warranted) prior to initiating therapy and periodically thereafter<\/li><li>biochemical test; prior to initiation, at wk 4, and periodically<\/li><li>women of childbearing potential; pregnancy test prior to initiating treatment, on a monthly basis during therapy, and for 6 months after discontinuation<\/li><li>liver function tests prior to initiating therapy and periodically thereafter<\/li><li>thyroid stimulating hormone test (TSH) prior to initiating therapy and periodically thereafter<\/li><li>ECG in patients with preexisting heart disease; prior to initiating therapy and periodically thereafter<\/li><li>eye exam at baseline in all patients, and periodically during therapy in patients with preexisting ophthalmologic disorders<\/li><li>respiratory function during inhalation therapy<\/li><li>pulmonary pressure every 2 to 4 hr in infants requiring mechanism ventilation; aerosol therapy in infants receiving ventilation; increase in expiratory pressures can occur if flow through aerosol generator is not adjusted properly, if expiratory valve is not frequently cleaned, and if one-way valves and filters are not used with ventilator lines;<\/li><li>fluid status during inhalation therapy<\/li><\/ul>"},{"id":"b1sas11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Capsule: 200 MG<\/li><li>Oral Tablet: 200 MG<\/li><\/ul><\/li><li><b>Copegus<\/b><br\/>Oral Tablet: 200 MG<br\/><\/li><li><b>Moderiba 1200 Dose Pack<\/b><br\/>Oral Tablet: 600 MG<br\/><\/li><li><b>Moderiba 800 Dose Pack<\/b><br\/>Oral Tablet: 400 MG<br\/><\/li><li><b>Moderiba<\/b><br\/>Oral Tablet: 200 MG<br\/><\/li><li><b>Rebetol<\/b><br\/><ul><li>Oral Capsule: 200 MG<\/li><li>Oral Solution: 40 MG\/ML<\/li><\/ul><\/li><li><b>Ribasphere<\/b><br\/><ul><li>Oral Capsule: 200 MG<\/li><li>Oral Tablet: 200 MG, 400 MG, 600 MG<\/li><\/ul><\/li><li><b>Ribasphere RibaPak<\/b><br\/>Oral Tablet: 400 MG, 600 MG<br\/><\/li><li><b>RibaTab<\/b><br\/>Oral Tablet: 400 MG, 600 MG<br\/><\/li><li><b>Ribavirin<\/b><br\/>Oral Capsule: 200 MG<br\/><\/li><li><b>Virazole<\/b><br\/>Inhalation Powder for Solution: 6 GM<br\/><\/li><\/ul>"},{"id":"b1sas12","title":"Toxicology","sub":[{"id":"b1sas12b31","title":"Clinical Effects","mono":"<b>RIBAVIRIN<\/b><br\/>OVERDOSE: Overdose information is limited. Clinical studies indicate primary effects to be increases in bilirubin and anemia followed by a rebound reticulocytosis. Headache, nausea and dizziness are also reported. Ribavirin becomes generally cytotoxic at greater than 100 times the ordinary serum levels produced by therapeutic doses. ADVERSE EFFECTS: INHALATION: In some cases, ribavirin has led to worsening pulmonary function (e.g., bronchospasm, pulmonary edema, hypoventilation, cyanosis, dyspnea, bacterial pneumonia, pneumothorax, apnea, atelectasis and ventilator dependence). Rarely, cardiac abnormalities have developed in patients following aerosolized ribavirin.  ORAL: Following ingestion, some patients have developed hemolytic anemia which may be associated with increased serum concentrations of bilirubin and uric acid.  Other effects have included  reticulocytosis, gastrointestinal disturbances  (eg, anorexia, dyspepsia, nausea), dizziness, insomnia, irritability, dyspnea, pharyngitis, skin rashes and pruritus. <br\/>"},{"id":"b1sas12b32","title":"Treatment","mono":"<b>RIBAVIRIN <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Activated charcoal, after large ingestion.<\/li><li>Enhanced elimination procedure: Hemodialysis does not remove significant amounts of ribavirin.  Plasma dialysis clearance in one patient averaged 93.9 mL\/min.<\/li><li>Monitoring of patient: Monitor CBC, serum bilirubin and vital signs in symptomatic patients. Obtain an ECG and institute continuous cardiac monitoring in symptomatic patients.<\/li><\/ul>"},{"id":"b1sas12b33","title":"Range of Toxicity","mono":"<b>RIBAVIRIN<\/b><br\/>TOXICITY: Aerosol administration of 2 g over 3 days was well tolerated without effects.  A 3 mg\/kg dose is expected to produce a peak level of 1 to 2 mcg\/mL.  Ribavirin becomes cytotoxic at levels of 200 to 1,000 mcg\/mL. THERAPEUTIC DOSE: ADULTS - 400 to 1200 mg orally in divided doses daily. CHILDREN - Refer to adult dosing if greater than 61 kg; or 400 to 800 mg orally in divided doses daily. INHALATION - Dose delivered cannot be precisely determined. Based on a particle size of 1.3 microns in diameter and retention factor of 0.7, it is estimated that an adult receives 0.82 mg\/kg\/hr. CHILDREN: Initial 20 mg\/mL in the drug reservoir of a small particle aerosol generator (SPAG-2) unit, with continuous aerosol administration for 12 to 18 hours\/day for 3 to 7 days.<br\/>"}]},{"id":"b1sas13","title":"Clinical Teaching","mono":"<ul><li>Pregnant women should not administer the inhaled form of drug or be near a patient during inhalation therapy.<\/li><li>Adverse effects to a fetus may be caused by either male or female patients receiving this drug. Emphasize the use of reliable contraception. This applies during treatment and up to 6 months post-therapy.<\/li><li>This drug may cause rash, pruritus, dyspepsia, anorexia, nausea, headache, conjunctivitis, rigors, and dry mouth.<\/li><li>Drug may also cause insomnia, depression, and fatigue.<\/li><li>Patient should report signs\/symptoms of severe depression and\/or suicidal ideation.<\/li><li>Instruct patient to report signs\/symptoms of respiratory deterioration, pancreatitis, hemolytic anemia, or cardiac deterioration.<\/li><li>Warn patient not to open, crush, or break the drug capsules, under any circumstances.<\/li><li>Patient should take the oral drug consistently with regard to food intake.<\/li><li>For inhaled form, advise patient on proper inhalation technique.<\/li><li>Patient should not mix inhaled form of drug with other aerosolized drugs.<\/li><\/ul>"}]}